Platform Development Sample Clauses

Platform Development executed in an agile manner with a two to four weeks sprint cadence, sprint demos and with a finishing release period with testing and deploy.
Sample 1
AutoNDA by SimpleDocs
Platform Development. BioMarine shall commercially develop and operate GMIT's platform complex situated on GMIT's leasehold into a mariculture facility in accordance with the plans and specifications outlined in Exhibit A hereto, including BioMarine's Sea Star Oyster Relay and Sea Trek Ocean Farming Systems.
Sample 1
Platform Development. LIVMOR will customize the Platform at its cost in accordance with the Platform Requirements in accordance with the Statement of Work No. 1 set forth on Exhibit A. LIVMOR will report to HeartBeam on no less than a bi-monthly basis on its progress against the development schedule set forth in Statement of Work No. 1. LIVMOR will ensure that the Platform contains the level of performance, features, and functionality that are no less than or no inferior to those of the LIVMOR Portal.
Sample 1
Platform Development. (a) Omeros shall within seventy-five (75) days of the Closing Date purchase the Platform free and clear of Liens other than Permitted Liens. Omeros will deliver an Exercise Notice (as defined in the Option Agreement) to Patobios for the acquisition of the Platform within forty-eight (48) hours of the execution of this Agreement by Omeros and Vulcan;
Sample 1
Platform Development. Aspire Holdings is a non-wholly owned subsidiary of the Company. Aspire Holdings entered into a Platform Development Master Agreement with each of the Company and CMCC on 10 January 2001. Details of these agreements were disclosed by the Company in compliance with the requirements of the Listing Rules in an announcement dated 10 January 2001. Pursuant to the two Platform Development Master Agreements, Aspire Holdings (or its subsidiaries) will provide the same scope of technology platform development and maintenance services to the Company, CMCC and their respective mobile telecommunications subsidiaries in various provinces, municipalities and autonomous regions in mainland China. These services include system and gateway integration services, hardware, software and system development (including development of applications), technical support and major overhaul services for the MISC Platform. -11- 14 -------------------------------------------------------------------------------- LETTER FROM THE BOARD -------------------------------------------------------------------------------- According to the Platform Development Master Agreements, each of the Company and CMCC will pay Aspire Holdings equipment charges, systems integration fees, software licensing fees, technical support fees and/or major overhaul charges, which will be determined according to standards laid down by the relevant governmental departments and/or by reference to market rates. As at the Latest Practicable Date, Aspire Holdings has commenced the provision of services pursuant to the Platform Development Master Agreements but no charges or fees have been paid by either the Company or CMCC to Aspire Holdings. UNDERTAKING PROVIDED BY CMCC CMCC, through CMHKG (a company in which CMCC has 100% economic interest), owns the entire issued share capital of CMBVI. CMBVI, in turn, is the immediate parent company of the Company holding approximately 75.6% of the issued share capital of the Company. CMCC has, in August 2000, undertaken in writing that, to the extent within CMCC's control, the Group will be treated equally with other cellular mobile communications operators in respect of all approvals, transactions and arrangements between the Group and CMCC and other cellular mobile communications entities controlled by CMCC. As most of the Group's Connected Transactions are with CMCC and its subsidiaries, the undertaking from CMCC would apply to the Connected Transactions described above. WAIVER OBTA...
Sample 1
Platform Development. Two Platform Development Master Agreements have been entered into between (i) Aspire Holdings and the Company; and (ii) Aspire Holdings and CMCC on 10 January 2001, pursuant to which Aspire Holdings (or its subsidiaries) will provide the same scope of technology platform development and maintenance services to the Company, CMCC and their respective mobile telecommunications subsidiaries in various provinces, municipalities and autonomous regions in Mainland China. The services include system and gateway integration services, hardware, software and system development (including development of applications), technical support and major overhaul services for the MISC Platform. Accordingly, each of the Company and CMCC will pay Aspire Holdings equipment charges, systems integration fees, software licensing fees, technical support fees and/or major overhaul charges, which will -24- 27 -------------------------------------------------------------------------------- LETTER FROM ROTHSCHILD -------------------------------------------------------------------------------- be determined according to standards laid down by the relevant governmental departments and/or by reference to market rates. As such, we are of the view that the Connected Transactions under the Platform Development Master Agreements are fair and reasonable so far as the Independent Shareholders are concerned. It should be noted that an upper limit for the payments by each of the Company and CMCC to Aspire Holdings in respect of the charges for these services will be imposed under the New Waiver which shall not exceed 3% of the Group's consolidated net tangible assets of the relevant financial year.
Sample 1
Platform Development. The main goal of this phase is to create a platform which allows individual investors to choose and invest in an individual commercial real estate property and receive recurring rental income. The platform has been developed and has launched. Phase I of business development has concluded and the company is preparing to move to Phase II. 21 ERC721 is another Ethereum technical standard that defines a set of behaviors and events that involve the movment, ownership, and information regarding non-fungible items.
Sample 1
AutoNDA by SimpleDocs
Platform Development. Participant acknowledges that Predix is a dynamically evolving platform and that GED may continually develop, deliver and provide ongoing innovation to the Platform Services. GED may update Platform Services in its ordinary course of business and such updates will be notified as part of the standard release cycle.
Sample 1
Platform Development 
Sample 1Sample 2Sample 3

Related to Platform Development

  • Clinical Development Licensee will have sole responsibility for and sole decision making over the clinical development of any Product arising from the Research Program in the Field. Notwithstanding the foregoing, if Licensee wishes to conduct clinical development of a Development Candidate at Penn and Penn has the clinical expertise, interest and ability to run such a trial as assessed at Penn’s sole discretion, such a study will be conducted under a separate Clinical Trial Agreement to be negotiated by the Parties prior to initiation of such study. Such separate clinical trial agreement will include a detailed clinical development plan, including costs and time lines for conducting the Clinical Trial.

  • Joint Development If joint development is involved, the Recipient agrees to follow the latest edition of FTA Circular 7050.1, “Federal Transit Administration Guidance on Joint Development.”

  • Development 3.3 Within twenty (20) Working Days after the Commencement Date and in accordance with paragraphs 3.10 to 3.12 (Amendment and Revision), the Contractor will prepare and deliver to the Authority for approval the full and final Security Plan which will be based on the draft Security Plan set out in Appendix B.

  • Information Systems Acquisition Development and Maintenance Security of System Files. To protect City Information Processing Systems and system files containing information, Service Provider will ensure that access to source code is restricted to authorized users whose specific job function necessitates such access.

  • Independent Development Receiving Party may currently or in the future be developing information internally, or receiving information internally, or receiving information from other parties that may be similar to the Disclosing Party's Confidential Information. Accordingly, nothing in this Agreement will be construed as a representation or inference that Receiving Party will not develop or have developed products or services, that, without violation of this Agreement, might compete with the products or systems contemplated by the Disclosing Party's Confidential Information.

  • Research Support opioid abatement research that may include, but is not limited to, the following:

  • Product Development Attach all requested documentation and attach additional pages as necessary. For all requirements include efforts of all Sublicensees. If not applicable, please so indicate by N/A.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Manufacturing (a) The Supplier shall without limitation be responsible, at no additional cost to the Purchaser, for: sourcing and procuring all raw materials for the Products; obtaining all necessary approvals, permits and licenses for the manufacturing of the Products; providing sufficient qualified staff and workers to perform the obligations under this Purchase Agreement; implementing and maintaining effective inventory and production control procedures with respect to the Products; and handling other matters as reasonably requested by the Purchaser from time to time.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

Time is Money Join Law Insider Premium to draft better contracts faster.